Clinical trial costs in Latin America are approximately 30% lower per-patient and trial timelines are 40% faster than in the US/EU, driven by favorable regulatory environments and efficient site operations across countries like Colombia, Mexico, Brazil, and Argentina.
Clinical trial sponsors can achieve substantial cost efficiencies by conducting studies in Latin America. On average, per-patient costs are approximately 30% lower compared to similar trials in the United States or European Union. This significant cost reduction is a crucial factor for medical device companies, particularly those engaged in First-in-Human (FIH) studies where budget optimization is often critical. The lower per-patient cost is influenced by several factors, including reduced investigator fees, lower site overheads, and a more favorable economic environment for clinical research operations.
For Phase 1/FIH medical device trials, the cost per patient in Latin America can range from $8,000 to $15,000 for standard device evaluations, whereas comparable studies in the US or EU might incur costs of $12,000 to $25,000 per patient. For pivotal trials, which typically involve larger patient cohorts and longer durations, the per-patient cost savings in Latin America become even more pronounced. These trials might see per-patient costs ranging from $15,000 to $35,000, compared to $25,000 to $60,000 or more in the US/EU. bioaccess® has supported 50+ clients in leveraging these savings, demonstrating consistent results across 10 countries.
Beyond cost advantages, Latin America offers a compelling advantage in terms of trial timelines. Studies in the region can be initiated and completed up to 40% faster than in the US or EU. This efficiency is largely attributable to the streamlined regulatory submission and approval processes overseen by national agencies such as INVIMA in Colombia, COFEPRIS in Mexico, ANVISA in Brazil, and ANMAT in Argentina. These agencies often collaborate or align with international benchmarks set by the FDA and ICH, ensuring high standards while facilitating quicker approvals. It is not uncommon for FIH medical device trials to achieve a start within 6-8 weeks from contract execution to first patient in. bioaccess® has a network of 200+ PIs, contributing to rapid patient recruitment and study completion.
Regulatory submission costs in Latin America are generally lower than in the US/EU. For instance, initial submission fees for a medical device trial might range from $3,000 to $8,000 in Latin American countries, whereas comparable fees in the US/EU can be upwards of $10,000 to $25,000. These figures do not include professional fees for dossier preparation and local representation, which also tend to be more competitive in the region. The expedited review timelines further reduce indirect costs associated with prolonged study setup phases.
Understanding the individual cost components is crucial for accurate budget planning. Below is a breakdown of typical expenditures for medical device trials, benchmarked for 2026, comparing Latin America to the US/EU.
| Cost Component | Latin America (Range) | US/EU (Range) |
|---|---|---|
| Per-Patient Cost (FIH Device) | $8,000 - $15,000 | $12,000 - $25,000 |
| Per-Patient Cost (Pivotal Device) | $15,000 - $35,000 | $25,000 - $60,000+ |
| Site Initiation Fees | $3,000 - $7,000 (per site) | $5,000 - $15,000 (per site) |
| IRB/EC Review Fees | $1,500 - $3,500 (per review) | $3,000 - $8,000 (per review) |
| Regulatory Submission Fees | $3,000 - $8,000 (initial) | $10,000 - $25,000 (initial) |
| Monitoring Fees (per visit) | $1,200 - $2,500 | $2,000 - $4,000 |
| Import/Export Logistics (device) | $500 - $2,000 (per shipment) | $1,000 - $4,000 (per shipment) |
| Project Management (monthly) | $8,000 - $15,000 | $15,000 - $30,000 |
Note: These are estimated ranges for 2026 and can vary based on study complexity, duration, and specific country regulations.
While Latin America generally offers significant cost advantages, specific country benchmarks can vary. Countries like Colombia, Mexico, Brazil, and Argentina are leading destinations for clinical trials, each presenting unique benefits.
When considering total study budgets for medical device trials, the cumulative savings in Latin America become highly compelling. For a typical single-arm FIH medical device study involving 10-20 patients, the total budget in Latin America could range from $200,000 to $500,000. A comparable study in the US or EU might easily cost $400,000 to $800,000+. For larger pivotal trials, which can enroll hundreds of patients, the total budget differences can be in the millions of dollars, representing substantial strategic savings for sponsors. bioaccess®'s expertise across 10 countries and 200+ PIs allows sponsors to optimize these budgets effectively.
These cost efficiencies, combined with accelerated timelines (40% faster than US/EU), make Latin America a strategic choice for medical device developers aiming to optimize their clinical development programs while adhering to international quality standards as mandated by regulators like FDA and ICH. bioaccess® focuses exclusively on these regions, providing unparalleled expertise and local access for its 50+ clients.", faq=[default_api.KbArticleFaq(question=
The primary cost advantage is approximately a 30% reduction in per-patient costs compared to conducting similar clinical trials in the United States or European Union. This significant saving applies to various study types, including First-in-Human (FIH) medical device trials and larger pivotal studies, making the region highly attractive for budget-conscious sponsors.
Clinical trial timelines, from study initiation to completion, can be up to 40% faster in Latin America than in the US/EU. This efficiency is largely due to streamlined regulatory processes by agencies such as INVIMA, COFEPRU, ANVISA, and ANMAT, which often provide quicker approvals without compromising ethical or scientific rigor. bioaccess® typically achieves a 6-8 week FIH start.
These countries offer a combination of factors: experienced investigators, diverse and large patient populations, modern medical infrastructure, and efficient regulatory bodies. Colombia (INVIMA), Mexico (COFEPRIS), Brazil (ANVISA), and Argentina (ANMAT) have well-defined, internationally aligned regulatory pathways that facilitate quicker study approvals and execution, all while maintaining high standards.
Yes, regulatory bodies in Latin American countries, such as INVIMA, COFEPRIS, ANVISA, and ANMAT, ensure that clinical trials adhere to rigorous international ethical and quality standards. These standards are typically aligned with guidelines from the FDA and ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), safeguarding patient welfare and data integrity across all studies.
A typical single-arm FIH medical device study involving 10-20 patients in Latin America could range from $200,000 to $500,000 in total budget. This is significantly lower than the $400,000 to $800,000+ that a comparable study might cost in the US or EU, demonstrating substantial budget optimization for sponsors.